AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17308327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15569397 — intervention group
Group type: EXPERIMENTAL
Intervention: Left 3 Hz rTMS
Number of subjects: 59
Study 15569397 — intervention group
Group type: EXPERIMENTAL
Intervention: Right 3 Hz rTMS
Number of subjects: 59
Study 15569397 — intervention group
Group type: EXPERIMENTAL
Intervention: Left 10 Hz rTMS
Number of subjects: 59
Study 15569397 — intervention group
Group type: EXPERIMENTAL
Intervention: Right 10 Hz rTMS
Number of subjects: 59
Study 15569397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine with sham rTMS
Number of subjects: 59
Study 12140629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistol-grip handles (PGH)
Number of subjects: 46
Study 12140629 — intervention group
Group type: COMPARATOR
Intervention: In-line handles (ILH)
Number of subjects: 46
Study 9865813 — intervention group
Group type: EXPERIMENTAL
Intervention: High structured treatment
Number of subjects: 119
Study 9865813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low structured treatment
Number of subjects: 119
Study 9865813 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 119
Study 9865813 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance group
Number of subjects: 119
Study 8929930 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management only (n = 96)
Number of subjects: 419
Study 8929930 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management with supported housing (n = 136)
Number of subjects: 419
Study 8929930 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 187)
Number of subjects: 419
Study 2649197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 100
Study 2649197 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 100
Study 333906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lung heparin (2 units/ml)
Number of subjects: 64
Study 333906 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine intestinal heparin (2 units/ml)
Number of subjects: 64
Study 333906 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride solution without heparin)
Number of subjects: 64
Study 333906 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bovine lung heparin and porcine intestinal heparin
Number of subjects: 64
Study 29205686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lower forearm median nerve block (group U)
Number of subjects: 100
Study 29205686 — intervention group
Group type: COMPARATOR
Intervention: Anatomic landmark-based blocking (group T)
Number of subjects: 100
Study 27806971 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) - 25% of energy requirements (2.3 ± 0.3 MJ)
Number of subjects: 18
Study 27806971 — intervention group
Group type: COMPARATOR
Intervention: Energy balance - 100% of energy requirements (9.3 ± 1.3 MJ)
Number of subjects: 18
Study 25115230 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio (nanohybrid composite)
Number of subjects: 31
Study 25115230 — intervention group
Group type: EXPERIMENTAL
Intervention: QuiXfil (microhybrid composite)
Number of subjects: 31
Study 25115230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Grandio and QuiXfil
Number of subjects: 31
Study 22468992 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 413
Study 22468992 — intervention group
Group type: COMPARATOR
Intervention: No-feedback control
Number of subjects: 413
Study 20687931 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based strategy (single capsule containing aspirin, a statin, and two blood pressure-lowering agents)
Number of subjects: 1000
Study 20687931 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study 20687931 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based strategy
Number of subjects: 1000
Study 18272344 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrapeptase 5mg + 1000 mg paracetamol
Number of subjects: 24
Study 18272344 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 1000 mg paracetamol
Number of subjects: 24
Study 16167356 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg twice a day for 3 days)
Number of subjects: 0
Study 16167356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to caffeine)
Number of subjects: 0
Study 16167356 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 16167356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12957423 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 450
Study 12957423 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 450
Study 12957423 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat stenting in large vessels (≥3 mm)
Number of subjects: 450
Study 12957423 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty in large vessels (≥3 mm)
Number of subjects: 450
Study 10798512 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (OBIWOM training program)
Number of subjects: 10
Study 10798512 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 10
Study 8719123 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 10
Study 8719123 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 10
Study 8719123 — intervention group
Group type: COMPARATOR
Intervention: pimozide 1 mg
Number of subjects: 10
Study 8719123 — intervention group
Group type: COMPARATOR
Intervention: pimozide 2 mg
Number of subjects: 10
Study 1389818 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-ups of 0.25% bupivacaine (group A)
Number of subjects: 80
Study 1389818 — intervention group
Group type: COMPARATOR
Intervention: Infusion of 0.125% bupivacaine (group B)
Number of subjects: 80
Study 3885918 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E2 (PGE2)
Number of subjects: 44
Study 3885918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28631234 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation quality and participant responsiveness
Number of subjects: 1721
Study 28631234 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage of the PATHS curriculum
Number of subjects: 1721
Study 28631234 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural fidelity and reach
Number of subjects: 1721
Study 27486124 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Falls Management Exercise (FaME) programme
Number of subjects: 80
Study 27486124 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (Control)
Number of subjects: 80
Study 24939489 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone (1.3 MAC)
Number of subjects: 50
Study 24939489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC) + low-dose i.v. remifentanil (0.028 μg/kg per minute)
Number of subjects: 50
Study 22898122 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-choice prompting software on PC for 5 workdays
Number of subjects: 28
Study 22898122 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 28
Study 20685927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual movement context with active movement
Number of subjects: 0
Study 20685927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dynamic or visuomotor perturbation in one bimanual context
Number of subjects: 0
Study 20685927 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement of one arm
Number of subjects: 0
Study 18661509 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Skill Training (CST) for nurses
Number of subjects: 89
Study 15943844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg/day
Number of subjects: 64
Study 15943844 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day
Number of subjects: 64
Study 15943844 — intervention group
Group type: COMPARATOR
Intervention: Tandospirone 30 mg/day
Number of subjects: 64
Study 12182218 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-vision goggles (NVGs)
Number of subjects: 0
Study 12182218 — intervention group
Group type: COMPARATOR
Intervention: No night-vision goggles (no NVGs)
Number of subjects: 0
Study 10568628 — intervention group
Group type: EXPERIMENTAL
Intervention: Six types of visual analogue scales (VAS): simple, middle-marked, graphic rating, graduated, graduated-numbered, and numerical rating
Number of subjects: 870
Study 10568628 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal and vertical orientations of VAS
Number of subjects: 870
Study 8739808 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg twice daily for 7 days
Number of subjects: 12
Study 8739808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1837713 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 4081
Study 1837713 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4081
Study 6354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine hydrochloride
Number of subjects: 0
Study 30707710 — intervention group
Group type: EXPERIMENTAL
Intervention: AlgoS (crisis cards for first-time attempters)
Number of subjects: 520
Study 30707710 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as usual)
Number of subjects: 520
Study 30707710 — intervention group
Group type: EXPERIMENTAL
Intervention: AlgoS (phone calls for non-first attempters)
Number of subjects: 520
Study 28070602 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (S34, S44, PC5) after NSAID intake
Number of subjects: 46
Study 28070602 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (nonspecific points) after NSAID intake
Number of subjects: 46
Study 28070602 — intervention group
Group type: COMPARATOR
Intervention: Drug-based treatment (NSAIDs only)
Number of subjects: 46
Study 27115567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (CisGem)
Number of subjects: 410
Study 27115567 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (Gem)
Number of subjects: 410
Study 25374434 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoRx Nexus TD-4280 blood glucose monitoring system
Number of subjects: 105
Study 22912474 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralized sunflower soapstock (NSS)
Number of subjects: 750
Study 22912474 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO)
Number of subjects: 750
Study 22912474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat levels (2%, 4%, 6%)
Number of subjects: 750
Study 19513783 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (PSE) using polyvinyl alcohol particles to achieve embolization of at least 50% of the distal branches of the splenic artery.
Number of subjects: 40
Study 19513783 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy with or without devascularization and left gastric ligation.
Number of subjects: 40
Study 18158850 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoSolve formulation (100 mg of CoQ(10) and 120 mg of vitamin E)
Number of subjects: 24
Study 18158850 — intervention group
Group type: COMPARATOR
Intervention: Pure substances in hard gelatin capsules (reference)
Number of subjects: 24
Study 15867044 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐OP (0.04 mug/kg per dose, twice daily)
Number of subjects: 243
Study 15867044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 15867044 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐OP
Number of subjects: 243
Study 12409567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux stent
Number of subjects: 50
Study 12409567 — intervention group
Group type: COMPARATOR
Intervention: Standard open stent
Number of subjects: 50
Study 12409567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9876788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with air
Number of subjects: 64
Study 9876788 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane with nitrous oxide
Number of subjects: 64
Study 7543598 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanoterone 200 mg
Number of subjects: 463
Study 7543598 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanoterone (100 to 800 mg)
Number of subjects: 463
Study 7543598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 1298631 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine loading dose of 20 mg/kg in 500 mls of normal saline or 5% dextrose infused over 4 hours followed by 100mg/kg infused 8 hourly for at least 24 hours
Number of subjects: 17
Study 1298631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quinine bisulfate 10mg/kg 8 hourly for a total of 7 days when patients were well enough (after initial loading dose)
Number of subjects: 17
Study 1298631 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without initial loading dose
Number of subjects: 17
Study 6470965 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (3000 mg of salicylate)
Number of subjects: 0
Study 6470965 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily (1500 mg of salicylate)
Number of subjects: 0
Study 6470965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage schedules
Number of subjects: 0
Study 30772699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care intervention (CCI) emphasizing nutritional ketosis
Number of subjects: 378
Study 30772699 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) treatment
Number of subjects: 378
Study 30025007 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-modified abutments
Number of subjects: 20
Study 30025007 — intervention group
Group type: COMPARATOR
Intervention: Machined abutments
Number of subjects: 20
Study 26952094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine
Number of subjects: 360
Study 26952094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg primaquine
Number of subjects: 360
Study 26952094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 24045403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP target of <150 mm Hg
Number of subjects: 65
Study 24045403 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP target of <180 mm Hg (control group)
Number of subjects: 65
Study 22409262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg apixaban
Number of subjects: 125
Study 22409262 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg apixaban
Number of subjects: 125
Study 22409262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg apixaban
Number of subjects: 125
Study 22409262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 19135657 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d for 12 weeks)
Number of subjects: 70
Study 19135657 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin (3.75 mg/mo for 12 weeks)
Number of subjects: 70
Study 18007100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector fluoride varnish
Number of subjects: 30
Study 18007100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 15632931 — intervention group
Group type: EXPERIMENTAL
Intervention: New pneumatic nasal tamponade (Rapid Rhino)
Number of subjects: 0
Study 15632931 — intervention group
Group type: COMPARATOR
Intervention: Choanal balloon tamponade
Number of subjects: 0
Study 12183351 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of lisuride
Number of subjects: 0
Study 12183351 — intervention group
Group type: COMPARATOR
Intervention: Oral levodopa and dopamine agonists (control)
Number of subjects: 0
Study 9209645 — intervention group
Group type: EXPERIMENTAL
Intervention: p18 gene deletion or rearrangement in MCL
Number of subjects: 60
Study 9209645 — intervention group
Group type: EXPERIMENTAL
Intervention: p18 abnormalities in MCL
Number of subjects: 60
Study 9209645 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations and deletions of CDKI p15 and p16 in MCL
Number of subjects: 60
Study 8358449 — intervention group
Group type: EXPERIMENTAL
Intervention: SUZI (Subzonal Insemination)
Number of subjects: 2
Study 8358449 — intervention group
Group type: COMPARATOR
Intervention: ZD (Zonal Dissection)
Number of subjects: 2
Study 3689626 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI 201-106 (30 mg)
Number of subjects: 20
Study 3689626 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI 201-106 (60 mg)
Number of subjects: 20
Study 30087742 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 44
Study 27331587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Sizing arm (14 sizes available)
Number of subjects: 496
Study 27331587 — intervention group
Group type: COMPARATOR
Intervention: Modified Sizing arm (7 sizes available)
Number of subjects: 496
Study 24796041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + rehabilitation (including hyperbaric oxygen and cognitive rehabilitation training)
Number of subjects: 73
Study 24796041 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation (including hyperbaric oxygen and cognitive rehabilitation training)
Number of subjects: 73
Study 24796041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + rehabilitation
Number of subjects: 73
Study 24796041 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 73
Study 22678640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and nasopharyngeal irrigation
Number of subjects: 2905
Study 20388917 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg/d intravenously and ciprofloxacin 2 × 200 mg/d intravenously
Number of subjects: 102
Study 20388917 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline and ciprofloxacin 2 × 200 mg/d intravenously (placebo group)
Number of subjects: 102
Study 18427974 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg/day (n = 70) on days 3-7 of the menstrual cycles
Number of subjects: 140
Study 18427974 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day combined with human menopausal gonadotropin (hMG) 75 IU/ml
Number of subjects: 140
Study 15671128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 40
Study 15671128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12841697 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg vaginal misoprostol 6 hourly (group 1, n = 60)
Number of subjects: 120
Study 10783352 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona-free embryos (Group A: 27 women; Group B: 30 women)
Number of subjects: 123
Study 10783352 — intervention group
Group type: COMPARATOR
Intervention: Zona-intact embryos (Group A: 25 women; Group B: 41 women)
Number of subjects: 123
Study 8842658 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% oxygen in nitrous oxide
Number of subjects: 101
Study 8842658 — intervention group
Group type: COMPARATOR
Intervention: 33% oxygen in air
Number of subjects: 101
Study 1400933 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) buserelin stopped on the same day as HMG treatment
Number of subjects: 63
Study 1400933 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRHa) buserelin continued during HMG treatment
Number of subjects: 63
Study 3890510 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg every 12 hours during low-dose week, 300 mg every 8 hours during high-dose week)
Number of subjects: 25
Study 3890510 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (200 mg every 6 hours during low-dose week, 400 mg every 6 hours during high-dose week)
Number of subjects: 25
Study 3890510 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 25
Study 3890510 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 25
Study 31653476 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention focusing on relationship processes (relationship satisfaction, positive problem-solving)
Number of subjects: 268
Study 29905631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block (USG) with 1% mepivacaine
Number of subjects: 84
Study 29905631 — intervention group
Group type: COMPARATOR
Intervention: Conventional block with 1% mepivacaine
Number of subjects: 84
Study 27912951 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic cold syrup
Number of subjects: 154
Study 27912951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 24418164 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 605
Study 24418164 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dual-Chamber Pacing (DDD)
Number of subjects: 605
Study 21701811 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight Training (OT) group
Number of subjects: 39
Study 21701811 — intervention group
Group type: COMPARATOR
Intervention: Overweight Detraining (OD) group
Number of subjects: 39
Study 20500881 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (2 hours of contact per fortnight for 6 months)
Number of subjects: 0
Study 20500881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19026272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic trials of bipolar disorder treatment
Number of subjects: 0
Study 19026272 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 16019355 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg plus estradiol valerate 2 mg daily
Number of subjects: 50
Study 16019355 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg daily
Number of subjects: 50
Study 12072848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting motion palpation
Number of subjects: 85